Drugs- Agents that affect bone mineral homeostasis (Kinder) Flashcards
raloxifene
aka Evista
Selective estrogen receptor modulators
alendronate
bisphosphonate
what regulates osteoclast production
osteoblast derived cytokines
what is the receptor for activating NF-KB (RANK)
an osteoclast protein whose expression is required for osteoclastic bone resorption
what is OPG
osteoprotegerin
produced by osteoblasts
acts as a decoy ligand for RANKL.
(1) Under conditions associated with increased bone resorption (estrogen deprivation) OPG is suppressed.
how long does the remodeling of bone cycle take
6 months
how does age related bone loss occur
vii) If replacement of resorbed bone precisely matched bone removed, remodeling would not change bone mass. However, small bone deficits persist after each cycle and life-long accumulation of these deficits leads to age-related bone loss.
how much Ca is in the diet about and how much is absorbed
600-1000 mg/day
100-250 mg absorbed in duodenum and jejunum , excreted in ileum
what percentage of filtered calcium is reabsorbed by the kidney
98%
what is the normal extracellular ca
8.5 - 10.4 mg/dL
normal extracellular phosphage levels
2.5 - 4.5 mg/dL
PTH effects on Ca and PO4
increases ca , decreased serum PO4
how does PTH affect bone
(1) PTH acts on osteoblasts to induce membrane bound and secreted soluble protein RANKL.
(2) RANKL acts on osteoclasts and osteoclast precursors to increase numbers and activity.
(3) These actions increase bone remodeling.
net effect is increased bone resorption
PTH affects on sclerostin
ii) PTH also inhibits production and secretion of sclerostin from osteocytes.
(1) Sclerostin blocks osteoblast proliferation.
(2) Thus, PTH directly increases proliferation of osteoblasts through sclerostin inhibition
PTH effects on kidney
iv) In kidney, PTH increases tubular reabsorption of Ca2+ and inhibits reabsorption of PO43-.
PTH effects on vitamin D
(1) PTH also stimulates 1,25(OH)2D production.
PTH effects on: magnesium amino acids bicarb sodium chloride sulfate
(2) Other effects: increased reabsorption of magnesium
and increased excretion of amino acids, bicarbonate, sodium, chloride, and sulfate.
what suppresses PTH production
i) Calcium-sensing receptor (CaSR) when stimulated by Ca2+ decreases PTH production.
ii) Vitamin D (1,25(OH)2D) also suppresses PTH production.
what is teriparatide
i) Synthetic, recombinant human parathyroid hormone (1-34)
ii) MOA: continuous administration of PTH causes bone demineralization and osteopenia; however, intermittent*** PTH (once daily subcutaneous injection) promotes bone growth.
what is the therapeutic use of teriparatide
iii) Therapeutic use: women with history of osteoporotic fracture, who have multiple risk factors for fracture, or who have failed (or are intolerant to) other drug therapy. Men with primary or hypogonadal osteoporosis.
(1) Has not been studied beyond two years of use – limit duration of therapy to two years.
what are the ADR’s of teriparatide
orthostatic hypotension, hypercalcemia, dizziness, nausea, hyperuricemia, and angina
what are the contraindications for teriparatide
CI: Teriparatide therapy is not advised in patients who are at an increased risk of osteosarcoma, such as those with Paget disease of the bone, unexplained elevations of alkaline phosphatase, open epiphyses, or prior radiation therapy involving the skeleton.
what does calcitriol (Vitamin D) do
augments intestinal absorption and retention of Ca2+ and PO43-.
increases bone turnover by:
i) Promoting the recruitment of osteoclast precursor cells to resorption sites.
ii) Promoting the development of differentiated functions that characterize mature osteoclasts.
iii) Inducing the synthesis of several proteins that regulate the bone mineralization process, such as RANK ligand and osteocalcin.
MOA of vitamin D analogs
i) MOA: increases intestinal absorption of Ca2+ and PO43- as well as bone turnover.